Financial Shenanigans

Financial Shenanigans — Reckitt Benckiser (RKT.L)

Reckitt's reported financials present two irreconcilable stories: a GAAP-loss company destroying equity, and a cash-generative branded consumer goods business producing over £2bn in annual free cash flow. The underlying cash generation is genuine. The forensic risks are also real and concentrated: a multi-billion contingent liability from NEC (necrotizing enterocolitis) infant formula litigation that carries zero provision in the accounts; goodwill write-downs the company's own impairment tests failed to anticipate for five years after a value-destructive acquisition; and a management earnings framework tied directly to executive compensation that strips out billions in write-downs. Overall classification: watchlist — the cash is trustworthy; the contingent balance sheet risks are not fully reflected in reported numbers.

1. Forensic Verdict

2. What The Financials Claim vs What They Indicate

Management's story: GAAP losses in FY2023 (£151m profit) and FY2024 (-£1,125m) reflect non-cash goodwill impairments on the IFCN (infant formula) business — a strategic mistake being corrected. Underlying Hygiene and Health divisions are performing well. Adjusted EBITDA of £3.1bn, FCF of £2.1bn, and a 7.3% dividend yield demonstrate financial health. Management targets FCF conversion above 90% of adjusted net income.

What the statements actually indicate: The adjusted story is largely correct on cash generation — FCF has been remarkably stable at £1.8-2.3bn across five years regardless of GAAP volatility, confirming the underlying business quality. The divergence is not in cash flows but in what is absent from the balance sheet: no provision for NEC litigation exposure that analysts independently estimate at £1-5bn; and the question of whether £6.3bn in goodwill write-downs on a £16.6bn acquisition should have been recognized years earlier.

3. The Most Important Shenanigan Risks

NEC Litigation — Zero Provision for a Material Known Risk

Under IAS 37 (provisions), a provision must be recognized when a present obligation exists, a cash outflow is probable, and a reliable estimate can be made. With a verdict already returned, thousands of cases pending in the MDL, and escalating trial activity, the "probable" threshold appears to be at or near the recognition threshold. The absence of any quantified provision — while legally understandable as a defense posture — creates material accounting-quality risk. A provision of even £1bn would represent an additional 95% of FY2024 GAAP net loss and 24% of current shareholders' equity.

Severity: Red. Confirm: any NEC provision disclosed in HY2025 or FY2025 results; further large MDL verdict. Clear: outright dismissal of the MDL, favorable bellwether verdict, or legislative immunity for infant formula manufacturers.

Delayed Goodwill Impairment Recognition

Forensic question: Were the £6.3bn in IFCN goodwill impairments recognized in a timely manner, or did management pass impairment tests that should have triggered earlier write-downs?

Evidence: Reckitt's own disclosures confirm that impairment assessments in both 2021 and 2022 concluded the IFCN recoverable amount exceeded its carrying value — no impairment required. Yet the following indicators were present or emerging throughout that period: the China IFCN business was sold in 2021 at a £2.5bn remeasurement loss; NEC litigation was emerging; US birth rates were declining; post-acquisition market share erosion was underway. The only period where IFCN performance genuinely improved was 2022 — when an Abbott competitor recall temporarily boosted Reckitt's nutrition volumes, providing management with defensible justification to defer impairment. Once the Abbott recall resolved, structural impairment was unavoidable, and £2.5bn was taken in FY2023 followed by £3.8bn in FY2024.

The quarterly income data makes the timing pattern stark: Q1-Q3 FY2024 delivered cumulative operating income of approximately £1,021m, then Q4 produced a -£1,981m operating loss driven entirely by the impairment taken in that single quarter. Revenue in Q4 (£3,255m) was virtually identical to the Q1-Q3 average (£3,348m) — this was a purely accounting event concentrated at year-end.

Why it matters: If impairments should have been recognized in 2021 or 2022, shareholders held overstated assets for 2-3 years. The management compensation framework — tied to adjusted EPS that excludes impairments — created an incentive structure that did not reward early recognition of economic losses.

Severity: Watch. Confirm: any regulatory review of CGU inputs; disclosure showing discount rates or terminal values used in 2021-22 impairment models were aggressive. Clear: evidence IFCN recoverable value genuinely exceeded carrying value in those years using conservative assumptions.

Adjusted vs Reported Earnings Gap and Compensation Linkage

Forensic question: Does the management-preferred earnings framework create a systematic incentive to understate the true cost of capital allocation mistakes?

Evidence: The gap between GAAP and adjusted earnings is extraordinary. FY2024: GAAP operating margin -7.2% vs adj EBITDA margin 23.3% — approximately 30 percentage points. FY2023: GAAP operating margin 4.3% vs adj EBITDA margin 26.0%. These gaps are dominated by goodwill impairments (~£3.8bn FY2024, ~£2.5bn FY2023) which are excluded from every adjusted metric. Executive remuneration is explicitly tied to adjusted EPS growth, FCF conversion, and LFL revenue growth — all of which exclude impairments. Management reported FY2024 adjusted EPS of approximately 340p while GAAP EPS was -158p.

The underlying cash flows appear genuine — the concern is structural framing. An investor relying solely on adjusted metrics misses £6.3bn of economic value destruction from an acquisition completed at 27x EBITDA in 2017.

Severity: Watch. The adjusted metrics are not fabricated; the issue is that they treat past capital destruction as if it never occurred.

Equity Erosion and GAAP-Loss Dividends

Evidence: Total equity fell from £9.2bn (FY2020) to £4.2bn (FY2024) — a 54% decline in five years. In FY2024, Reckitt paid £1,245m in dividends and £500m in buybacks (£1,745m total) while reporting a GAAP net loss of £1,125m. Net debt/EBITDA has risen from 1.4x (FY2020) to 1.9x (FY2024), approaching the top of management's stated 1.5-2.0x target range.

Capital returns are covered by FCF at approximately 1.20x — the cash is real. The issue is that any NEC cash settlement or further IFCN impairment would compress this coverage and accelerate equity erosion in a balance sheet already reduced by 54%.

Severity: Watch.

Cash Generation Is Genuine and Consistent

Severity: Green — confirmed by cross-statement consistency over five years.

Auditor Change — Regulatory Rotation, Not a Red Flag

KPMG has been Reckitt's statutory auditor since FY2018. In June 2025, Reckitt announced PwC as successor auditor from FY2026, following a competitive tender required by UK mandatory audit rotation rules (compulsory switch every 10 years). No restatements, qualified opinions, material weakness disclosures, or going concern warnings are evident from available data. The change is a compliance event, not a signal.

Severity: Green.

4. Earnings Quality And Cash Reality

In FY2020-FY2022, OCF and net income tracked closely at a ~1.2x ratio — normal for a capital-light branded goods business with ~£400-430m annual capex. From FY2023, the relationship broke: net income collapsed to £151m and -£1,125m while OCF held at £2.7bn and £2.6bn respectively. This divergence is entirely non-cash — driven by the £2.5bn (FY2023) and £3.82bn (FY2024) IFCN goodwill impairments. FCF tracked OCF closely throughout, confirming the impairments are accounting charges, not cash outflows. No evidence of working-capital timing, vendor financing, or operating-to-investing reclassification.

FCF has covered total capital returns in every year. The coverage multiple has ranged from 1.20x (FY2024) to 1.32x (FY2023), but has compressed from 1.28x (FY2021) to 1.20x (FY2024). The dividend is cash-covered — but compression is a directional warning. Any NEC cash settlement or FCF softening narrows the buffer further.

Gross margins have been stable at 57.8-59.8% — a forensically clean signal with no pattern of channel stuffing, aggressive trade promotion, or cost deferral. Adjusted EBITDA margin has held at ~26-27% for most of the period but compressed to 23.3% in FY2024, likely reflecting IFCN revenue decline and cost pressure in the Nutrition segment. The gap between gross margin and EBITDA margin (~35pp) represents SG&A, R&D, and restructuring charges — broadly stable and consistent with a branded FMCG business.

No evidence of receivables inflation, inventory build-up, or payables stretching. Working capital dynamics are consistent with a branded FMCG business managing normal trade terms.

5. Cross-Statement Contradictions

The only material cross-statement surprise is the Q4 FY2024 quarterly discontinuity.

Revenue in Q4 (£3,255m) was virtually identical to Q1 (£3,312m), Q2 (£3,523m), and Q3 (£3,256m). Operating income collapsed from a Q1-Q3 average of +£340m to -£1,981m. Q4 operating cash flow of £565m was, however, consistent with Q1-Q3 levels (£612m, £734m, £656m), confirming this is purely an accounting event. The entire £3.82bn impairment was booked in Q4 — a year-end lump. This is the impairment timing question in concrete form: why was a charge material enough to turn the year-end from breakeven to a £1.1bn loss not recognized earlier in the year when the strategic review and NEC litigation escalation were already underway?

Are there other cross-statement contradictions? No material ones. Revenue and receivable days are consistent (52 debtor days stable over time). OCF and EBITDA-capex-interest-tax reconcile cleanly. Debt levels and interest expense are consistent (£7.1bn debt at ~5.1% implied rate ≈ £365m interest ✓). Balance sheet movements and cash flow working capital lines are internally coherent. The financial statements are internally consistent on everything except the goodwill carrying value versus economic reality.

6. True Economic Reality

Strip out the non-cash impairments and the picture that emerges is a genuinely profitable, cash-generative business — but with a contingent liability not yet in the accounts.

The FCF line tells the real story: £1.8-2.3bn annually, irrespective of the GAAP volatility. EBITDA has been steady at £3.1-3.8bn. The modest compression in FY2024 (EBITDA £3,105m vs £3,785m in FY2023) is real and warrants monitoring — it reflects IFCN revenue pressure as the strategic review proceeds.

Goodwill has declined from £17.9bn to £11.2bn — a £6.7bn reduction from IFCN impairments. Equity has halved from £9.2bn to £4.2bn. Debt has remained broadly stable (£6.7-7.1bn), meaning the balance sheet deterioration is crystallization of real economic losses, not financial engineering. The good news: net debt/EBITDA of 1.9x remains within management's 1.5-2.0x target. The risk: any NEC cash settlement (analyst range £1-5bn) would breach 2.0x and materially impair the dividend.

Normalized earnings estimate (FY2024):

FCF of £2,089m is the most reliable proxy for true earnings after interest, taxes, and maintenance capex. Estimated normalized cash EBIT: EBITDA (£3,105m) minus D&A (£245m) = £2,860m. After estimated cash interest (£365m) and cash taxes (approximately £450m at ~18% rate), normalized cash earnings are approximately £2,000-2,100m — consistent with observed FCF, confirming the internal coherence of the numbers.

What GAAP under-states: £6.3bn in cumulative impairments are real economic losses from the 2017 Mead Johnson acquisition overpayment — not accounting artifacts. The capital was destroyed when the acquisition was consummated; the P&L is recognizing reality belatedly.

What GAAP over-states (adjusted metrics): Approximately £1-5bn in potential NEC liability is absent from the balance sheet entirely. The adjusted earnings framework, by design, directs investor attention away from cumulative capital destruction and presents business quality in its best light. Both things can be simultaneously true: the core Hygiene/Health business is genuinely high quality, and the capital allocation history was genuinely poor.

7. Watchlist

What would worsen forensic risk:

The MDL bellwether NEC trial set for July 2026 is the single most important near-term forensic event. An adverse verdict comparable to the $495m Abbott ruling would almost certainly force recognition of a material IAS 37 provision, potentially consuming 50-100%+ of a year's FCF and creating credit-metric stress. The securities class action (alleging management misled investors on NEC risks from January 2021 to July 2024) adds compounding litigation exposure.

Any increase in adjusted-EBITDA add-backs beyond D&A and impairments — for example, expanding restructuring exclusions, capitalizing operating costs, or changing revenue recognition timing — would constitute a new red flag. A revenue decline spreading from IFCN into the Hygiene or Health divisions would erode the FCF floor that currently justifies the watchlist rather than avoid classification.

What would clear the risk:

Resolution of NEC litigation through settlement or MDL dismissal — particularly if accompanied by a disclosed and reserved provision — would be the single largest de-risking event. A confirmed IFCN disposal at or above current carrying value (£11.2bn goodwill + £5.7bn intangibles) would remove the litigation exposure from consolidated accounts, crystallize any residual impairment, and demonstrate that the strategic review can create value. Clean PwC audit sign-off on FY2025 accounts (first year under new auditor) with no qualification, control weakness, or restatement would be a material positive signal.

Continued FCF stability above £1.8bn, maintenance of net debt/EBITDA below 2.0x, and no broadening of one-time add-backs in the adjusted earnings bridge are all necessary conditions to remain at watchlist rather than escalating.

Next filing items to watch:

FY2025 results (expected March 2026): First full-year audit by PwC. NEC provision decision — any language shift from "contingent" to "probable obligation" in the IAS 37 note is highly material. IFCN disposal progress and carrying value. EBITDA margin trend in Hygiene and Health divisions.

July 2026 MDL trial: Any verdict creates immediate provisioning pressure regardless of appeals. Settlement discussions before trial date would be an early signal.

HY2025 results (July 2025 — now published): Updated contingent liability language. Any recognition of partial NEC provision. FCF run-rate vs prior year.